Andrea Boutros, Medical Doctor and Oncology Resident at San Martino Polyclinic Hospital, shared a post on X about a recent article he and his colleagues co-authored, adding:
“Adjuvant PD-1 blockade in high-risk CSCC might soon become the standard.
But should it? Divergent ph 3 results highlight uncertainty, while neoadjuvant approaches may offer more with less.
Our thoughts in EJCancer.”
Title: Is earlier better? Rethinking timing of immunotherapy in cutaneous squamous cell carcinoma
Authors: Francesco Spagnolo, Andrea Boutros, Mario Mandalà
Read the Full Article on EJCancer
More posts featuring Cutaneous Squamous Cell Carcinoma.